92 related articles for article (PubMed ID: 22619997)
1. [Biomarker development by cancer proteomics].
Kondo T
Nihon Rinsho; 2012 May; 70(5):754-8. PubMed ID: 22619997
[TBL] [Abstract][Full Text] [Related]
2. Pfetin as a prognostic biomarker of gastrointestinal stromal tumors revealed by proteomics.
Suehara Y; Kondo T; Seki K; Shibata T; Fujii K; Gotoh M; Hasegawa T; Shimada Y; Sasako M; Shimoda T; Kurosawa H; Beppu Y; Kawai A; Hirohashi S
Clin Cancer Res; 2008 Mar; 14(6):1707-17. PubMed ID: 18347171
[TBL] [Abstract][Full Text] [Related]
3. [Proteomics for biomarker development toward personalized medicine].
Kondo T
Rinsho Byori; 2012 Jul; 60(7):644-9. PubMed ID: 22973724
[TBL] [Abstract][Full Text] [Related]
4. Proteomic approach toward personalized sarcoma treatment: lessons from prognostic biomarker discovery in gastrointestinal stromal tumor.
Kondo T; Suehara Y; Kikuta K; Kubota D; Tajima T; Mukaihara K; Ichikawa H; Kawai A
Proteomics Clin Appl; 2013 Jan; 7(1-2):70-8. PubMed ID: 23281253
[TBL] [Abstract][Full Text] [Related]
5. Pfetin as a prognostic biomarker in gastrointestinal stromal tumor: novel monoclonal antibody and external validation study in multiple clinical facilities.
Kikuta K; Gotoh M; Kanda T; Tochigi N; Shimoda T; Hasegawa T; Katai H; Shimada Y; Suehara Y; Kawai A; Hirohashi S; Kondo T
Jpn J Clin Oncol; 2010 Jan; 40(1):60-72. PubMed ID: 19815537
[TBL] [Abstract][Full Text] [Related]
6. Pfetin as a prognostic biomarker for gastrointestinal stromal tumor: validation study in multiple clinical facilities.
Kubota D; Orita H; Yoshida A; Gotoh M; Kanda T; Tsuda H; Hasegawa T; Katai H; Shimada Y; Kaneko K; Kawai A; Kondo T
Jpn J Clin Oncol; 2011 Oct; 41(10):1194-202. PubMed ID: 21903705
[TBL] [Abstract][Full Text] [Related]
7. The prognostic value of pfetin: a validation study in gastrointestinal stromal tumors using a commercially available antibody.
Kubota D; Mukaihara K; Yoshida A; Suehara Y; Saito T; Okubo T; Gotoh M; Orita H; Tsuda H; Kaneko K; Kawai A; Kondo T; Sato K; Yao T
Jpn J Clin Oncol; 2013 Jun; 43(6):669-75. PubMed ID: 23619989
[TBL] [Abstract][Full Text] [Related]
8. Validation study on pfetin and ATP-dependent RNA helicase DDX39 as prognostic biomarkers in gastrointestinal stromal tumour.
Kubota D; Okubo T; Saito T; Suehara Y; Yoshida A; Kikuta K; Tsuda H; Katai H; Shimada Y; Kaneko K; Kawai A; Kondo T
Jpn J Clin Oncol; 2012 Aug; 42(8):730-41. PubMed ID: 22723667
[TBL] [Abstract][Full Text] [Related]
9. Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis.
Mearadji A; den Bakker MA; van Geel AN; Eggermont AM; Sleijfer S; Verweij J; de Wilt JH; Verhoef C
Anticancer Drugs; 2008 Jul; 19(6):607-12. PubMed ID: 18525320
[TBL] [Abstract][Full Text] [Related]
10. Gastrointestinal stromal tumors: risk assessment and adjuvant therapy.
Joensuu H
Hematol Oncol Clin North Am; 2013 Oct; 27(5):889-904. PubMed ID: 24093166
[TBL] [Abstract][Full Text] [Related]
11. Pfetin as a risk factor of recurrence in gastrointestinal stromal tumors.
Orita H; Ito T; Kushida T; Sakurada M; Maekawa H; Wada R; Suehara Y; Kubota D; Sato K
Biomed Res Int; 2014; 2014():651935. PubMed ID: 24977158
[TBL] [Abstract][Full Text] [Related]
12. Expression of Bcl-2 in gastrointestinal stromal tumors: correlation with progression-free survival in 81 patients treated with imatinib mesylate.
Steinert DM; Oyarzo M; Wang X; Choi H; Thall PF; Medeiros LJ; Raymond AK; Benjamin RS; Zhang W; Trent JC
Cancer; 2006 Apr; 106(7):1617-23. PubMed ID: 16518826
[TBL] [Abstract][Full Text] [Related]
13. Gastrointestinal stromal tumors (GIST).
Landi B; Bouche O; Blay JY
Gastroenterol Clin Biol; 2006 Sep; 30 Spec No 2():2S98-2S101. PubMed ID: 17151569
[No Abstract] [Full Text] [Related]
14. Use of potassium channel tetramerization domain-containing 12 as a biomarker for diagnosis and prognosis of gastrointestinal stromal tumor.
Hasegawa T; Asanuma H; Ogino J; Hirohashi Y; Shinomura Y; Iwaki H; Kikuchi H; Kondo T
Hum Pathol; 2013 Jul; 44(7):1271-7. PubMed ID: 23290008
[TBL] [Abstract][Full Text] [Related]
15. Clinical proteomics identified ATP-dependent RNA helicase DDX39 as a novel biomarker to predict poor prognosis of patients with gastrointestinal stromal tumor.
Kikuta K; Kubota D; Saito T; Orita H; Yoshida A; Tsuda H; Suehara Y; Katai H; Shimada Y; Toyama Y; Sato K; Yao T; Kaneko K; Beppu Y; Murakami Y; Kawai A; Kondo T
J Proteomics; 2012 Feb; 75(4):1089-98. PubMed ID: 22119546
[TBL] [Abstract][Full Text] [Related]
16. Prognostic analysis of patients with gastrointestinal stromal tumors: a single unit experience with surgical treatment of primary disease.
Cao H; Zhang Y; Wang M; Shen DP; Sheng ZY; Ni XZ; Wu ZY; Liu Q; Shen YY; Song YY
Chin Med J (Engl); 2010 Jan; 123(2):131-6. PubMed ID: 20137358
[TBL] [Abstract][Full Text] [Related]
17. [Novel tumor marker discovery of gastrointestinal cancers using various proteomic approaches].
Tomonaga T; Nomura F
Rinsho Byori; 2007 Jan; 55(1):63-8. PubMed ID: 17319493
[TBL] [Abstract][Full Text] [Related]
18. Application of 2D-DIGE in cancer proteomics toward personalized medicine.
Kondo T; Hirohashi S
Methods Mol Biol; 2009; 577():135-54. PubMed ID: 19718514
[TBL] [Abstract][Full Text] [Related]
19. Advanced proteomic technologies for cancer biomarker discovery.
Wong SC; Chan CM; Ma BB; Lam MY; Choi GC; Au TC; Chan AS; Chan AT
Expert Rev Proteomics; 2009 Apr; 6(2):123-34. PubMed ID: 19385940
[TBL] [Abstract][Full Text] [Related]
20. Outcome of metastatic GIST in the era before tyrosine kinase inhibitors.
Gold JS; van der Zwan SM; Gönen M; Maki RG; Singer S; Brennan MF; Antonescu CR; De Matteo RP
Ann Surg Oncol; 2007 Jan; 14(1):134-42. PubMed ID: 17080234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
